57-22-7 Vincristine

Superiority:

Product Name: Vincristine
Synonyms: Vincristine (base and/or unspecified salts);Vincristine ,VCR, NSC-67574, Oncovin;Cristovin;Leucid;Pericristine;Vincosid;(2'β)-22-Oxovincaleukoblastine;methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(1R,13S,15R,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0,12.0,1]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0
CAS: 57-22-7
MF: C46H56N4O10
MW: 824.96
EINECS: 200-318-1
Product Categories: chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract
Mol File: 57-22-7.mol

Vincristine Chemical Properties
Melting point  211-216 ºC
alpha  D25 +17°; D25 +26.2° (ethylene chloride)
Boiling point  761.92°C (rough estimate)
density  1.1539 (rough estimate)
refractive index  1.6000 (estimate)
pka 5.4(at 25℃)
Stability: Stable, but may be heat sensitive. Incompatible with strong oxidizing agents.
CAS DataBase Reference 57-22-7
EPA Substance Registry System Vincristine (57-22-7)
Safety Information
RIDADR  1544
HazardClass  6.1(a)
PackingGroup  II
Hazardous Substances Data 57-22-7(Hazardous Substances Data)
Toxicity LD50 i.p. in mice: 5.2 mg/kg (Adamson)
MSDS Information
Vincristine Usage And Synthesis
Chemical Properties solid
Uses Antineoplastic[Note—Graphic formula same as for Vinblastine Sulfate, except that R is CHO].
Brand name Oncovin (Lilly); Vincasar (Sicor).
General Description A white crystalline solid. Melting point 218°C. Used as an antineoplastic.
Health Hazard Highly toxic, may be fatal if inhaled, swallowed or absorbed through skin. Avoid any skin contact. Effects of contact or inhalation may be delayed. Fire may produce irritating, corrosive and/or toxic gases. Runoff from fire control or dilution water may be corrosive and/or toxic and cause pollution.
Fire Hazard Flash point data for Vincristine are not available, but Vincristine is probably combustible.
Clinical Use Vincristine is an important component of the curative combination chemotherapy for acute lymphoblastic leukemia, Hodgkin’s disease (the MOPP regimen), and non-Hodgkin’s lymphomas. It is also used in several regimens for pediatric solid tumors, including Wilms’ tumor, Ewing’s sarcoma, rhabdomyosarcoma, and neuroblastoma; in adult tumors of the breast, lung, and cervix; and in sarcomas. Its relative lack of myelosuppression makes it more attractive than vinblastine for use in combination with myelotoxic drugs.Vinblastine is especially useful in testicular carcinomas and is also active in Hodgkin’s disease, other types of lymphomas, breast cancer, and renal cell carcinoma.